Why is Abbott Laboratories stock up 2.8% today?

Traders Union
All News
Financial News
Abbott surges 2.87% today on earnings

Highlights

Abbott Laboratories delivered second-quarter adjusted EPS of $1.31, exceeding expectations and prompting a full-year earnings guidance raise.
Revenue climbed 13% year-over-year, driven by strong Medical Devices and Diagnostics growth, with $2.1 billion returned to shareholders via dividends and buybacks.
Technical indicators reflect short-term bullish momentum with the stock near resistance at $101.74, forecast to trade between $94.65 and $108.67, with a 77% probability of upside.

Raised guidance and shareholder returns lift optimism despite revenue miss

Abbott Laboratories reported second quarter 2026 adjusted diluted earnings per share of $1.31, surpassing Wall Street estimates. Quarterly revenue reached $12.59 billion, modestly below some forecasts, but sales increased 13% on a reported basis and 4.8% on a comparable basis. Full-year adjusted earnings guidance was raised as Medical Devices and Diagnostics segments performed strongly. The company also returned $2.1 billion to shareholders through dividends and share repurchases during the quarter.

Anton Kharitonov, expert at Traders Union, sees Abbott’s uptrend as fragile. Momentum above short-term averages masks that the price still lags the 200-day mark. He notes that while adjusted EPS beat, revenue fell short of consensus — raising doubts about the underlying strength. Overbought technicals and elevated volatility further restrain conviction for a sustained rally. "Unless the stock recaptures the $109.99 level decisively, risk of a reversal remains significant despite improved guidance," he cautions.

Viktoras Karapetjanc, expert at Traders Union, views Abbott’s earnings beat and upgraded outlook as strong drivers. He highlights robust momentum in Medical Devices and Diagnostics, supported by $2.1 billion returned to shareholders. With bullish sentiment and a 77% probability of further gains, the positive structure should persist. "As long as ABT holds above $100.3, I expect continued upside and see attractive opportunities in this market environment," he states.

Jainam Mehta, market strategist, notes ABT’s current oscillation between support at $100.3 and resistance at $101.74. He sees mixed technical signals, with buyer dominance and short-term momentum but caution from overbought oscillators. Given increased volatility, Mehta suggests tactical trades may arise from fades at extremes or a potential breakout. "If ABT can sustain momentum past $101.74, the risk-reward for bullish setups improves sharply," he says.

Mixed momentum signals as price tests technical resistance

Abbott Laboratories is trading above its 20-day ($92.4) and 50-day ($89.38) moving averages, signaling short- and medium-term positive momentum, but remains below the 200-day moving average ($109.99), reflecting longer-term bearish alignment. The nearest support is at $100.3 and resistance is at $101.74, with the Ichimoku Kijun ($94.4) serving as distant trend confirmation. Momentum indicators are mixed; the MACD signals strong buy while the ADX is neutral. The RSI at 64.1 and CCI at 171.17 suggest overbought conditions, further echoed by Stochastic RSI and Bull/Bear Power readings. Intraday momentum is dominated by buyers, and volatility is elevated.

Earlier, analysts noted that Abbott Laboratories demonstrated near-term strength following upbeat earnings while still facing longer-term technical resistance. The latest price action reinforces the recovery narrative but with overbought signals now in place, a sustained break above $101.74 would be needed to confirm renewed bullish momentum.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.